Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi

Blood (2023) 142 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2023-183002

Published: 2023

Journal Articles

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

David Tong Chen, Olga Goloubeva, Hanan Alkhaldi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Djordje Atanackovic, Mehmet Hakan Kocoglu, Forat Lutfi, Jean A. Yared

Blood (2022) 140 (Supplement 1): 9526–9527.

https://doi.org/10.1182/blood-2022-158281

Published: 2022

Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood (2021) 138 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2021-154225

Published: 2021

Journal Articles

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Justin N. Malinou, MD, Hanan Alkhaldi, MD, Saurabh Dahiya, MD, Olga Goloubeva, PhD MSc, Ali Bukhari, MD, Forat Lutfi, MD, Gabriela Sanchez-Petitto, MD, Santanu Samanta, MD, Aaron P. Rapoport, MD, Nancy M. Hardy, MD, Nicolette Minas, MS, Kathleen Ruehle, RN, Natalie Gahres, RN, Linda Ridge, RN, BA, CCTC, Pranshu Mohindra, MD, Jason Molitoris, MD, Jean A. Yared, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142140

Published: 2020

Journal Articles

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Gabriela Sanchez-Petitto, MD, Olga Goloubeva, PhD MSc, James Childress, MD, Tahreem Iqbal, MD, Jack Masur, MD, Max An, BS, Safwan Muhammad, MD, Justin Lawson, PharmD BCOP, Jasmin Sahbaz, MD, Brian Barr, MD, Vu H. Duong, MD, Jennie Y. Law, MD, Ashkan Emadi, MD, PhD, Maria R. Baer, MD, Sandrine Niyongere, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138534

Published: 2020

Journal Articles

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Kshama A. Doshi, PhD, Shivani Kapoor, MS, Ying Zou, MD PhD, Xiang Li, PhD, Mario Scarpa, MS, Nidal Muvarak, PhD, Pratik Nagaria, PhD, Olga Goloubeva, PhD MSc, Adriana E. Tron, PhD, Charles J. Bieberich, PhD, Feyruz V. Rassool, BSc, PhD, Maria R. Baer, MD

Blood (2017) 130 (Supplement 1): 1243.

https://doi.org/10.1182/blood.V130.Suppl_1.1243.1243

Published: 2017

Journal Articles

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Cameron Dell, BS, Olga Goloubeva, PhD MSc, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Nancy M. Hardy, MD, Jean Yared, MD, Ning Ma, CRNP, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 2177.

https://doi.org/10.1182/blood.V130.Suppl_1.2177.2177

Published: 2017

Journal Articles

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Noa G. Holtzman, MD, Olga Goloubeva, PhD MSc, Zeba Singh, MBBS, Sameer Sawhney, MD, Ying Zou, MD PhD, Jean Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Ashraf Z. Badros, MD

Blood (2017) 130 (Supplement 1): 3035.

https://doi.org/10.1182/blood.V130.Suppl_1.3035.3035

Published: 2017

Journal Articles

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P. Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba Singh

Blood (2017) 130 (10): 1189–1197.

https://doi.org/10.1182/blood-2017-03-775122

Published: 2017

Includes: Supplemental data

Journal Articles

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z Badros, MD, Elizabeth Hyjek, MD PhD, Ning Ma, Alexander M. Lesokhin, MD, Aaron P. Rapoport, MD, Mehmet H. Kocoglu, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Ashlee Johnson, Cameron Dell, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2016) 128 (22): 490.

https://doi.org/10.1182/blood.V128.22.490.490

Published: 2016

Journal Articles

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

Shahbaz A. Malik, MD, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Z Badros, MD, Nancy M. Hardy, MD, Mehmet H. Kocoglu, MD, Alison Duffy, Kathleen Ruehle, Jennifer Nishioka, Olga Goloubeva, PhD, Jean Yared, MD

Blood (2015) 126 (23): 5507.

https://doi.org/10.1182/blood.V126.23.5507.5507

Published: 2015

Journal Articles

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ashraf Z. Badros, MD, Mehmet H. Kocoglu, MD, Ning Ma, NP, Aaron P. Rapoport, MD, Emily Lederer, RN, Sunita Philip, MBBS, Patricia Lesho, Cameron Dell, Nancy M. Hardy, MD, Jean Yared, MD, Olga Goloubeva, PhD, Zeba Singh, MD

Blood (2015) 126 (23): 506.

https://doi.org/10.1182/blood.V126.23.506.506

Published: 2015

Journal Articles

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Vishal Bhatnagar, MD, Yin Wu, MD, Olga Goloubeva, Kathleen Ruehle, RN, Todd Milliron, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Badros, MD

Blood (2013) 122 (21): 2951.

https://doi.org/10.1182/blood.V122.21.2951.2951

Published: 2013

Journal Articles

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Ashraf Badros, MD, Sunita Philip, Patricia Lesho, Mariola Sadowska, Dianna Weikel, Timothy Meiller, Rena Lapidus, Lisa Hester, Todd Milliron, Olga Goloubeva

Blood (2013) 122 (21): 3153.

https://doi.org/10.1182/blood.V122.21.3153.3153

Published: 2013

Journal Articles

A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma (MM) Patients.

Ting Bao, MD, Neil Porter, MD, James Primrose, RN, Olga Goloubeva, Lisa Hester, Lulu Wang, MS, Mariola Sadowska, PhD, Rena Lapidus, PhD, Michelle Medeiros, MS, MA, Lixing Lao, PhD, L.Ac., Susan Dorsey, RN, PhD, Ashraf Z. Badros, MD

Blood (2012) 120 (21): 3168.

https://doi.org/10.1182/blood.V120.21.3168.3168

Published: 2012

Journal Articles

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Ashraf Z. Badros, MD, Sunita Philip, Patricia Lesho, Dianna Weikel, Olga Goloubeva, Mariola Sadowska, Rena Lapidus, PhD, Lisa Hester, Todd Milliron, Timothy Meiller

Blood (2012) 120 (21): 4245.

https://doi.org/10.1182/blood.V120.21.4245.4245

Published: 2012

Journal Articles

Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.

Yin Wu, MD, Olga Goloubeva, PhD, Kathleen Ruehle, Saul Yanovich, MD, Aaron P. Rapoport, MD, Gorgun Akpek, MD, MS, Ashraf Z. Badros, MD

Blood (2008) 112 (11): 3327.

https://doi.org/10.1182/blood.V112.11.3327.3327

Published: 2008

Journal Articles

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Ashraf Badros, MD, Jay S. Dalal, MD, Olga Goloubeva, PhD, Jenni Thompson, Phrm.D., Kelly Yager, RN, Can Ilyas, MD, Aaron P. Rapoport, MD, Robert G. Fenton, MD, PhD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 3534.

https://doi.org/10.1182/blood.V108.11.3534.3534

Published: 2006

Journal Articles

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

Ashraf Z. Badros, MD, Olga Goloubeva, PhD, Saranya Chumsri, MD, Kathleen Ruehle, RN, Yi Ning, PhD, Joann Meekins, PhD, Liliana Guedez, PhD, Aaron P. Rapoport, MD, Barry Meisenberg, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5024.

https://doi.org/10.1182/blood.V108.11.5024.5024

Published: 2006

Journal Articles

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Ashraf Badros, MD, Olga Goloubeva, PhD, Dianna Weikel, DDS, Aaron P. Rapoport, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Timothy Meiller, DDS, PhD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5026.

https://doi.org/10.1182/blood.V108.11.5026.5026

Published: 2006

NARROW

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Concurrent Treatment with Pim Kinase Inhibitor Downregulates Alternative Non-Homologous End-Joining Repair and Decreases Genomic Instability in FLT3-ITD Cells Treated with Topoisomerase 2 Inhibitor Chemotherapy Drugs

Similar Survival for African American and Caucasian Multiple Myeloma Patients Receiving Auto-SCT

Plasma Cell Leukemia (PCL): Clinical Characteristics, Outcomes, and the Impact of Circulating Plasma Cells (CPC) Percentage — A Single Center Experience

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma (MM) Patients.

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Clinical Presentation, Prognostic Factors and Treatment Outcome of Multiple Myeloma (MM) in African American (AA) Patients.

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only